Keros Therapeutics, Inc. (NASDAQ: KROS) director Charles W. Newton sold 550 shares of the company's common stock on June 11, 2026, with the transaction totaling $5,521. The shares were sold at prices ranging from $9.83 to $10.16 per share. The timing of the sale comes as the stock trades near its 52-week low of $9.69, with shares down 52% over the past six months. Despite the recent decline, InvestingPro analysis suggests the stock is undervalued, with a Fair Value of $13.98 compared to the current price of $10.24. The company maintains a market capitalization of $200.69 million. These sales were executed pursuant to a Rule 10b5-1 trading plan, which Mr. Newton adopted on March 12, 2026. Following these transactions, Mr. Newton directly owns 12,665 shares of Keros Therapeutics common stock.
This transaction highlights the intersection of executive activity and market valuation metrics. The sale price range of $9.83 to $10.16 per share aligns closely with the current trading price, reflecting the stock's recent performance. The use of a Rule 10b5-1 trading plan, adopted on March 12, 2026, indicates a pre-arranged strategy for selling shares, which is a common mechanism for executives to manage their holdings while complying with regulatory requirements.
InvestingPro's analysis of KROS suggests that the stock may be undervalued, with a fair value estimate of $13.98 compared to the current price of $10.24. This discrepancy between the fair value and the current market price could indicate a potential opportunity for investors, although it is important to consider the stock's recent performance and the broader market context.
Key points regarding the article include the sale of 550 shares by Charles W. Newton, the total transaction value of $5,521, and the stock's recent performance, including its 52% decline over the past six months and its proximity to the 52-week low. The article also highlights the use of a Rule 10b5-1 trading plan, which is a pre-arranged strategy for selling shares.
Risks or uncertainties explicitly supported by the article include the stock's recent decline of 52% over the past six months and its proximity to the 52-week low of $9.69. These factors could indicate continued downward pressure on the stock price, although the undervaluation analysis suggests a potential counterbalance.